Journals / Turkish Neurosurgery / 2020 / Cilt: 30 - Sayı: 5

Effect of Antithrombotic Therapy on Development of Acute Subdural Hematoma After Burr Hole Drainage of Chronic Subdural Hematoma

Pages
758–762
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although theliterature suggests that antiplatelet and anticoagulant drugs to be discontinued between 5 and 7 days before surgery, our resultsshowed that acute hemorrhage was not detected in any patient who underwent surgery more than 72 hours after referral.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To evaluate the relationship between the time from cessation of anticoagulant/antiplatelet medication to surgery and risk ofpostoperative acute subdural hematoma (ASDH) after burr hole drainage of chronic subdural hematoma (CSDH).MATERIAL and METHODS: A retrospective study of patients who underwent burr hole drainage of CSDH between December 2014and December 2019 was performed.
📊
Key Findings & Data:Patients were divided into 3 groups based on time from referral to surgery: 72 hours.RESULTS: One hundred seventeen patients underwent burr hole drainage of CSDH during the 5-year study period.
💡
Conclusion & Impact:Although theliterature suggests that antiplatelet and anticoagulant drugs to be discontinued between 5 and 7 days before surgery, our resultsshowed that acute hemorrhage was not detected in any patient who underwent surgery more than 72 hours after referral.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

AIM: To evaluate the relationship between the time from cessation of anticoagulant/antiplatelet medication to surgery and risk ofpostoperative acute subdural hematoma (ASDH) after burr hole drainage of chronic subdural hematoma (CSDH).MATERIAL and METHODS: A retrospective study of patients who underwent burr hole drainage of CSDH between December 2014and December 2019 was performed. Demographic and clinical data regarding age, gender, medication (antithrombotic therapy),smoking, daily alcohol consumption, history of head trauma, presenting symptoms, and neurological examination were collectedfrom the medical records. Patients were divided into 3 groups based on time from referral to surgery: 72 hours.RESULTS: One hundred seventeen patients underwent burr hole drainage of CSDH during the 5-year study period. Seventy-twopatients were male (61.5%) and 45 were female (38.5%). Mean age was 70.5 ± 7.2 years. Postoperative ASDH occurred in 2 of the32 patients (6.3%) who were not taking antithrombotic medication and 6 of the 85 patients (7.1%) who were taking antithromboticmedication. The difference was not significant (p=0.797).CONCLUSION: The risk of ASDH after burr hole drainage of CSDH was not affected by antithrombotic medication. Although theliterature suggests that antiplatelet and anticoagulant drugs to be discontinued between 5 and 7 days before surgery, our resultsshowed that acute hemorrhage was not detected in any patient who underwent surgery more than 72 hours after referral.

🔖

Cite This Article

YÜKSEL, M. O., ÇEVİK, S., ERDOĞAN, B., TUNÇKALE, T., KATAR, S., IŞIK, S., ÇALIŞKAN, T., EVRAN, Ş. (2020). Effect of Antithrombotic Therapy on Development of Acute Subdural Hematoma After Burr Hole Drainage of Chronic Subdural Hematoma. Turkish Neurosurgery, Cilt: 30 - Sayı: 5, 758–762. https://ajindex.com/articles/404370

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Amano T, Matsuo S, Miyamatsu Y, Yamashita S, Nakamizo A: Impact of antithrombotic therapy on surgical treatment in patients with chronic subdural hematoma. J Clin Neurosci 74:55-60, 2020 2. Baechli H, Nordmann A, Bucher HC, Gratzl O: Demographics and prevalent risk factors of chronic subdural haematoma: Results of a large single-center cohort study. Neurosurg Rev 27:263-266, 2004 3. Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, DeRosa PL, Andersen KN, Sussman E, Carpenter A, Connolly ES Jr: The surgical management of chronic subdural hematoma. Neurosurg Rev 35:155-169
  2. discussion 169, 2012 4. Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson PJ: Pathophysiology of chronic subdural haematoma: Inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation 14:108, 2017 5. Gonugunta V, Buxton N: Warfarin and chronic subdural haematomas. Br J Neurosurg 15:514-517, 2001 6. Guha D, Coyne S, Macdonald RL: Timing of the resumption of antithrombotic agents following surgical evacuation of chronic subdural hematomas: A retrospective cohort study. J Neurosurg 124:750-759, 2016 7. Huang KT, Bi WL, Abd-El-Barr M, Yan SC, Tafel IJ, Dunn IF, Gormley WB: The neurocritical and neurosurgical care of subdural hematomas. Neurocrit Care 24:294-307, 2016 8. Ito H, Komai T, Yamamoto S: Fibrinolytic enzyme in the lining walls of chronic subdural hematoma. J Neurosurg 48:197- 200, 1978 9. Ito H, Yamamoto S, Komai T, Mizukoshi H: Role of local hyperfibrinolysis in the etiology of chronic subdural hematoma. J Neurosurg 45:26-31, 1976 10. Javadi SA, Naderi F, Javadi AM: The optimal surgical approach for treatment of chronic subdural hematoma: Questionnaire assessment of practice in iran and review of literature. Acta Med Iran 53:617-621, 2015 11. Kawamata T, Takeshita M, Kubo O, Izawa M, Kagawa M, Takakura K: Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol 44:438- 442
  3. discussion 443, 1995 12. Lee KS: Natural history of chronic subdural haematoma. Brain Inj 18:351-358, 2004 13. Markwalder TM: Chronic subdural hematomas: A review. J Neurosurg 54:637-645, 1981 14. McMillian WD, Rogers FB: Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: A review. J Trauma 66:942-950, 2009 15. Mega JL, Simon T: Pharmacology of antithrombotic drugs: An assessment of oral antiplatelet and anticoagulant treatments. Lancet 386:281-291, 2015 16. Moore MM, Pasquale MD, Badellino M: Im